ReutersCodex · 实盘观望把握 5/10
北京时间·🕒 发布 15:15:11时区推断·⟳ 抓取 15:20:22·⚡ 决策 07-13 23:04:25 +7h44m·105.9 天前
GSK 的 Jemperli 在 dMMR/MSI-H 局部晚期直肠癌 II 期 AZUR-1 试验达到主要终点
事件方向对 Jemperli 资产为正面：GSK 确认 AZUR-1 达到主要终点，并计划向全球监管机构提交数据。
📄 原文Reuters↗ 原文
GSK (GSK.L) said on Monday its cancer drug Jemperli met the primary goal of a mid-stage trial, with a clinically sign…
不做 GSK（GSK.US）
Jemperli 直肠癌数据为正面但对 GSK 1046 亿美元市值短线弹性有限，且核心适应症叙事已在 2024 年突破性疗法资格和早期数据中传播。
观望 AnaptysBio（ANAB.US）
ANAB 对 Jemperli royalty 弹性更高，但低档 royalty 已被 Sagard 货币化、近 20 日已明显上涨，且本次是预告过的 H2 数据兑现，需等监管提交/获批或 royalty 现金流归属更清晰后再评估。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- GSK 此前已披露 FDA Breakthrough Therapy Designation，依据为 dMMR/MSI-H 局部晚期直肠癌 42 名完成治疗患者 100% 临床完全缓解的初步证据，说明核心医学叙事不是全新。
- Reuters 报道 GSK 称 Jemperli 在 AZUR-1 中期 II 期直肠癌试验达到主要终点，并提到 2025 年销售额约 11 亿美元。
- GSK 官网同日发布新闻稿确认 AZUR-1 数据，并说明 Jemperli 尚未在全球任何地区获批用于直肠癌。市场反应:截至 2026-07-13 15:02 UTC，GSK.US 日内约 -1.08%，ANAB.US 日内约 +1.36%，未出现强烈正向重定价。
关键理由
- 事件方向对 Jemperli 资产为正面：GSK 确认 AZUR-1 达到主要终点，并计划向全球监管机构提交数据。
- 量级上，Jemperli 2025 年销售约 11 亿美元、GSK 市值约 1046 亿美元，本次直肠癌适应症虽可强化长期峰值销售预期，但对 GSK 短线市值弹性有限。
- AnaptysBio 享有 Jemperli 销售里程碑与高于 10 亿美元销售额部分 12%-25% 的分层 royalty，但其低档 royalty 已被 Sagard 货币化，且当前催化是已预告的 H2 2026 关键读数兑现。
主要风险
- 直肠癌适应症尚未获批，GSK 官网也提示 Jemperli 目前全球尚未获批用于直肠癌，后续监管提交、审评和商业渗透仍有不确定性。
- ANAB 近 20 日已上涨约 19%，且 2024 年已有同适应症 100% cCR 与 FDA Breakthrough Therapy 传播，当前读数存在预期内兑现和见光死风险。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-01 · 影响 weakens
BioPharma Dive 报道 GSK 与 AnaptysBio 围绕 Jemperli 收入互诉，且 ANAB 对 Sagard 仍有最高 6.75 亿美元相关义务，削弱 royalty 资产的简单直通估值。
检索:ANAB stock recent bearish risk Jemperli Sagard royalties lawsuit 2026 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-07-13 · 影响 weakens
GSK 官方资料明确 Jemperli 目前未在全球任何地区获批用于直肠癌，本次仍需监管审评，短线商业收入增量尚未落地。
检索:GSK Jemperli AZUR-1 risk not approved rectal cancer analyst 2026 原文 ↗ - 做多前查反向 · 来源 stock_quote · 日期 2026-07-13 · 影响 weakens
GSK 日内下跌、ANAB 日内小涨但近 20 日已涨约 19%，没有显示该新闻带来立即、强烈的新资金重定价。
检索:stock_quote GSK.US full; stock_quote ANAB.US full
工具调用 · 历史记录,结果未知(2 种)
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 1,465 字
GSK (GSK.L) said on Monday its cancer drug Jemperli met the primary goal of a mid-stage trial, with a clinically significant rate of patients showing no detectable signs of cancer for one year or more after treatment for a specific type of locally advanced rectal cancer.
Here are some details:
Dostarlimab, marketed as Jemperli, is being tested in rectal cancer tumours that cannot properly repair DNA damage, a subtype affecting 5%-10% of 730,000 annual global cases, according to GSK.
Current standard of care typically includes chemotherapy, radiation and surgery, and can lead to lifelong colostomy bag use and infertility.
These tumours have a genetic characteristic where they cannot properly repair DNA damage, causing mutations to accumulate and making them highly responsive to immunotherapies like Jemperli.
The interim data from the phase II AZUR-1 trial also showed dostarlimab's safety and tolerability profile was consistent with previous studies in solid tumours.
Jemperli, already approved in the U.S. and UK for specific endometrial cancer subtypes, generated sales of $1.1 billion in 2025, and GSK expects it to be an important contributor to its long-term sales target of more than £40 billion ($53.52 billion) by 2031.
The drug has received both Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration, and GSK plans to share data with global regulators for review.
($1 = £0.7474)
Here are some details:
Dostarlimab, marketed as Jemperli, is being tested in rectal cancer tumours that cannot properly repair DNA damage, a subtype affecting 5%-10% of 730,000 annual global cases, according to GSK.
Current standard of care typically includes chemotherapy, radiation and surgery, and can lead to lifelong colostomy bag use and infertility.
These tumours have a genetic characteristic where they cannot properly repair DNA damage, causing mutations to accumulate and making them highly responsive to immunotherapies like Jemperli.
The interim data from the phase II AZUR-1 trial also showed dostarlimab's safety and tolerability profile was consistent with previous studies in solid tumours.
Jemperli, already approved in the U.S. and UK for specific endometrial cancer subtypes, generated sales of $1.1 billion in 2025, and GSK expects it to be an important contributor to its long-term sales target of more than £40 billion ($53.52 billion) by 2031.
The drug has received both Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration, and GSK plans to share data with global regulators for review.
($1 = £0.7474)
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。